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Abstract
Background: A previous study had identified 45 items assessing the impact of atopic dermatitis (AD) on
the whole family. From these it was intended to develop two separate scales, one assessing impact on
carers and the other determining the effect on the child.
Methods: The 45 items were included in three clinical trials designed to test the efficacy of a new topical
treatment (pimecrolimus, Elidel cream 1%) in the treatment of AD in infants and children and in validation
studies in the UK, US, Germany, France and the Netherlands. Rasch analyses were undertaken to
determine whether an internationally valid, unidimensional scale could be developed that would inform on
the direct impact of AD on the child.
Results: Rasch analyses applied to the data from the trials indicated that the draft measure consisted of
two scales, one assessing the QoL of the carer and the other (consisting of 12 items) measuring the impact
of AD on the child. Three of the 12 potential items failed to fit the measurement model in Europe and five
in the US. In addition, four items exhibiting differential item functioning (DIF) by country were identified.
After removing the misfitting items and controlling for DIF it was possible to derive a scale; The Childhood
Impact of Atopic Dermatitis (CIAD) with good item fit for each trial analysis. Analysis of the validation data
from each of the different countries confirmed that the CIAD had adequate internal consistency,
reproducibility and construct validity.
The CIAD demonstrated the benefits of treatment with Elidel over placebo in the European trial. A similar
(non-significant) trend was found for the US trials.
Conclusion: The study represents a novel method of dealing with the problem of DIF associated with
different cultures. Such problems are likely to arise in any multinational study involving patient-reported
outcome measures, as items in the scales are likely to be valued differently in different cultures. However,
where all items in a scale fit both a single theoretical construct and the Rasch measurement model, it is
feasible to conceive of outcome measures with a different set of items in each language.
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Background
Paediatric atopic dermatitis (AD) is a common skin con-
dition affecting 12–15% of children in early childhood
[1]. There is a wide variation in the experience of symp-
toms which, although mild for a majority of children, are
subject to unpredictable exacerbations. The disease can
have considerable impact on children and their develop-
ment [2,3] and family life may also be disrupted by the
condition [4-6].
A major problem in the assessment of the impact of AD
on very young children is their inability to provide the
necessary information. Consequently, an alternative
approach was taken by McKenna and colleagues [7] who
undertook a study designed to look at the impact of the
disease and its treatment on the family as a whole. Quali-
tative interviews were conducted with the principal carers
of affected children to identify items for inclusion in a
QoL questionnaire. Forty-five potential items were identi-
fied covering issues of relevance to the affected child and
to his or her siblings and parents. This item set was
included in three clinical trials (two in the US and one in
Europe) designed to test the efficacy of a new topical treat-
ment for AD (pimecrolimus, Elidel® 1% cream) in the
treatment of AD in children.
In parallel with the trials, validation studies of the new
instrument were conducted in the UK, US, France, Ger-
many and the Netherlands. Rasch analyses applied to the
data from these validation studies indicated that the 45
draft items split into two separate scales. The first scale
included items such as 'I feel I have no time to relax' and 'I
worry about the way he looks', that were concerned with the
parent's QoL. This was named the Parents' Index of Qual-
ity of Life – Atopic Dermatitis (PIQoL-AD). This scale was
shown to be unidimensional and to have good internal
consistency, test-retest reliability and construct validity
[7]. The measure proved effective in the trials in establish-
ing the QoL benefits for parents when Elidel cream is
compared to conventional therapy in the treatment of
children with AD [8].
A second potential scale was identified that included
potential items such as 'He is very moody' and 'He is very
demanding' that were concerned with the direct impact of
AD on the affected child (as reported by the parent) [7]. It
is important to note that these items relate to issues that
are observable rather than covering social or emotional
impacts of which the parent may not be aware.
The present paper reports on analyses undertaken to
determine whether the twelve child-specific items could
be combined to form a unidimensional scale. If a valid
scale could be identified from these items it was intended
to call it the CIAD (Childhood Impact of Atopic Dermati-
tis).
During the development of the PIQoL-AD particular
attention had been paid to the production of language
versions that would allow trial data to be combined from
different countries. It is generally assumed that a measure,
where carefully adapted, will be equivalent across lan-
guage versions, allowing data to be combined validly.
Unfortunately, evidence derived from applying the Rasch
model to data from different language versions of the
same measure does not support this assumption. For
example, experience with the Recurrent Genital Herpes
Quality of Life questionnaire (RGHQoL) in recurrent gen-
ital herpes indicates that the item, Herpes makes me feel
dirty  is valued differently in the US and Germany [9].
Application of the measure suggests that a positive
response to this item indicates greater impairment of QoL
in the US than in Germany. Such differences are likely to
be related to cultural issues that are beyond the scope of
the traditional method of adapting questionnaires. In the
case of the PIQoL-AD, the method of simultaneous devel-
opment of different language versions ensured that such
cultural differences were kept to a minimum. This was
achieved by ensuring that items included in the measure
had been raised as important issues in each country where
patient interviews were completed and by extensive test-
ing of the draft questionnaire with samples of patients in
each country for which a version was developed. Items
that exhibited differential item functioning between
countries were also removed from the measure.
The present analyses were also designed to determine
whether the CIAD can be applied validly in all five coun-
tries in which validation studies were conducted.
Methods
For the present analyses only the 12 items directly relevant
to the impact of AD on the affected child were considered.
A 'True'/'Not true' response format was employed in these
items. All the items used are gender specific with parallel
versions of the measure being available for parents of boys
and parents of girls.
Three sets of analysis were conducted:
1. Rasch analyses were conducted on the trial data to iden-
tify whether a unidimensional scale could be identified
that assessed the direct impact of AD on the child.
2. Analyses of the country-specific validation studies were
conducted to test the psychometric properties of the iden-
tified scale.Health and Quality of Life Outcomes 2007, 5:45 http://www.hqlo.com/content/5/1/45
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3. Finally, the trial data were re-analysed to determine the
direct effect of Elidel on the child as assessed by the CAID.
1. Trial analyses to identify unidimensional CIAD scale
Data were collected from three double-blind, multi-
center, randomized, parallel-group studies in which
patients aged 3 months to 18 years were recruited and ran-
domized to either pimecrolimus cream 1% or vehicle
cream (in addition to emollients as skincare and medium
potency topical steroids for treatment of severe flares) in a
2:1 ratio, respectively. CIAD data were available from par-
ents of children aged up to eight years in the UK, France,
Germany, the Netherlands and USA.
In the European trial participants were followed for 12
months with assessments made at baseline, 6 weeks, 6
months and 12 months (Times 1 to 4). Two hundred and
eight participants entered the study, of whom, 140
(67.3%) were in the Elidel group and 68 (32.7%) in the
placebo (vehicle) group.
In the two US trials, assessments were made at baseline, 6
weeks and 6 months (Times 1 to 3), when the studies were
terminated. For the present analyses, the data from these
two studies are combined and referred to as the US trial.
Of the 261 participants who entered the study, 243 pro-
vided a baseline assessment. Of these, 159 (65.4%) were
in the Elidel group and 84 (34.6%) in the placebo group.
Rasch analyses
Rasch analyses were conducted on the data from the clin-
ical trials in order to determine whether unidimensional
CIAD scales could be identified. Separate analyses were
run for the US trials and the European trial.
The Rasch model [10] is an unidimensional model that,
in educational settings makes the assertion: that the easier
an item (question) is the more likely it will be passed, and
that the more able a person, the more likely he or she will
be to pass an item. It assumes that the probability of a
respondent passing a particular item is a logistic function
of the relative distance between the item location and the
respondent location on a linear scale. In other words, the
probability that a person will affirm an item is a logistic
function of the difference between the person's ability [θ]
and the difficulty of the item [b] (i.e. the ability required
to affirm item i), and only a function of that difference.
where pni is the probability that person n will answer item
i correctly [or be able to do the task specified by that item],
θ is person ability, and b is the item difficulty parameter.
From this, the expected pattern of responses to an item set
is determined given the estimated θ. and b. When the
observed response pattern coincides with, or does not
deviate greatly from, the expected response pattern, the
items constitute a true Rasch scale [11]. Taken with confir-
mation of local independence of items – that is, the
absence of residual associations in the data after the Rasch
trait has been removed – unidimensionality is confirmed.
This model has seen extensive use in the development of
health outcome measurement in general [11-20] and also
in child-related scales [21]. In health outcome measure-
ment person ability translates to the level of trait (for
example, disease severity, functional capacity, or QoL)
exhibited by the person and item difficulty to the level of
disease severity or (for example) functional capacity man-
ifest in the item. According to the Rasch model, an indi-
vidual with a severe level of disease would be highly likely
to affirm (in the case of a dichotomous item) an item that
represented a mild level of the disease.
Within the framework of Rasch measurement, cross-cul-
tural validity can be examined. Essentially, the scale
should work in the same way irrespective of which cul-
tural group is assessed. Thus, the location of items along
the measurement construct should remain the same
between countries. This type of analysis is given the name
differential item functioning (DIF) [22]. An individual's
responses to items should not be affected by factors (such
as age, gender and culture) external to the scale and the
trait being assessed. DIF occurs when one of these external
factors means that one group (for example, males) are sig-
nificantly more or less likely to affirm an item (or score
significantly higher on an item) than females. The basis of
the DIF approach lies in the item response function, the S-
shaped trace of the proportion of individuals at the same
level of trait who affirm an item. Under the requirement
that the trait under consideration is unidimensional, if the
item measures the same trait across groups then, except
for random variations, the same curve should be found
irrespective of the nature of the group for which a function
is plotted. Items that do not yield the same item response
function for two or more groups exhibit DIF and violate
the requirement of unidimensionality. The statistical test
of DIF is an ANOVA of the residuals.
As noted above, identically worded items may have differ-
ent PRO values in different cultures (a common cause of
DIF). Where some but not all items display such DIF, it is
possible to treat them as a different item in each country.
This is illustrated in Table 1, where Item 1 effectively rep-
resents a separate item in each country and is linked by
item 2). This procedure is referred to as "splitting" items
across countries. The analysis is re-run on the new item
sets. Finally, a Principal Components Analysis (PCA) of
the residuals is undertaken to confirm the assumption of
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local independence of items and thus unidimensionality
of the scale. The residual is the difference between what is
expected and what is observed and represents what
remains when the 'Rasch factor' has been extracted from
the data. Therefore, the first factor of the PCA is the pri-
mary contributor to the variance of the data when this
Rasch factor has been discounted. If the first factor of the
PCA accounts for less than 30% of the variance, we can
conclude that the scale is undimensional [23].
Time-points for each participant were included as separate
and individual observations for the analysis to ensure that
all time points were calibrated onto the same logit scale.
This meant that each person was entered into the analysis
three or four times, once for each time point. Data from
the European and US trials were calibrated separately.
Such an approach is essential when determining change
in score on a PRO over time.
Chi2 statistics were used to evaluate individual item and
overall scale fit to the Rasch model. Significant Chi2 statis-
tics are indicative of inadequate fit to the model. Due to
the number of statistical tests undertaken, Bonferroni cor-
rections were applied to fit analyses [24]. The Rasch anal-
ysis employed RUMM 2010 software [25].
2. Country-specific validation studies
Following identification of unidimensional CIAD scales it
was necessary to analyze the validation study results from
each country to determine whether the measures were
reliable and valid. Separate studies were conducted in
each country (in parallel with the trials) to determine the
psychometric properties of the new measure. Details of
the samples are shown in Table 2.
Reliability
The reliability of the CIAD was assessed using the test-
retest method. Where an instrument is required for use in
a clinical trial or for monitoring individual patients, a
high reliability is desirable (that is, a correlation coeffi-
cient of at least 0.85) [26].
Internal consistency
Internal consistency was assessed using Cronbach's alpha
coefficients. Values below 0.70 are indicative of individual
items not contributing adequately to the overall scale
[27].
Validity
Construct validity was tested by assessing known groups
validity. Scores on the CIAD were related to perceived
severity of disease, whether or not the child was experienc-
ing a flare-up and whether or not the face or hands were
affected. Differences in QoL scores between the assess-
ment groups were tested by Mann-Whitney U Test where
there were two independent groups or Kruskal-Wallis
One-way Analysis of Variance where there were three or
more independent groups.
3. Application of the CIAD in the clinical trials
All trial analyses were carried out on an intention to treat
(ITT) data set, using last observation carried forward (for
total score – not for individual item missing data).
A simple ANOVA model was employed to examine base-
line differences in QoL scores. Analysis of Covariance
models were used to test for differences in change scores.
The analyses were performed on the logit person estimates
obtained from the Rasch analyses, which were then trans-
formed into integers on a 0–100 scale.
An α-level of 0.05 was adopted.
Results
Identification of the CIAD for the European trial
Working with the 12 items that were specific to the child,
the scale was initially analyzed separately for the four
countries (France, Germany, The Netherlands and the
UK). Overall fit of the data to the Rasch model ranged
from acceptable to good within these countries. Germany
and France each had one item that displayed misfit.
When the data were pooled across countries, initial over-
all fit of the data to the model was poor and three items;
'Other children won't play with her', 'She can't join in activities
with other children', and 'She sleeps badly most nights', were
found to misfit.
Analysis by country revealed four items that displayed sig-
nificant DIF, displaying a differential impact of AD across
these countries. These items were; 'She whinges all the time',
'She is very moody', 'She often gets angry with me' and 'She
cannot be comforted'. Post hoc analysis (Tukey's Test) on
these items revealed that the UK and the Netherlands were
the countries that displayed most significant difference on
Table 1: Example of adjustment for DIF by splitting item across countries
Country Item 1a Item 1b Item 1c Item 2
A* *
B**
C **Health and Quality of Life Outcomes 2007, 5:45 http://www.hqlo.com/content/5/1/45
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these items. Consequently, these four items were each
split into three separate items; one for the UK alone, one
for the Netherlands alone and one for Germany and
France together.
This produced a 20-item scale (eight link/original items
and 12 split items). Analysis of this scale revealed that the
same three items misfit as with the original 12-item scale.
Removal of these items produced good overall fit of the
data to the Rasch model, Chi2 = 117.88, df = 75, p <
0.002.(see Table 3)
Principal components analysis (PCA) of the residuals
indicated that the first residual factor explained 16% of
the variance. As only a small proportion of the variance
was explained both the assumption of local independence
and unidimensionality were confirmed.
Identification of the CIAD for the US trial
Initial fit of the 12 items was poor and five items had to
be deleted before a good fit to the model was found. These
items were; 'Other children don't like holding her hand', 'She
can't join in activities with other children', 'She is often irrita-
ble', 'She whinges all the time' and 'She sleeps badly most
nights'. Following the removal of these items, overall fit to
the model was good: Chi2 = 42.58, df = 28, p < 0.004.
Once again the PCA of the residuals explained little (21%)
of the variance.
Traditional psychometric properties of the CIAD
Having identified the item sets for the CIAD in Europe
and the US the validation data from each country were
analyzed to ensure that the new scale had adequate psy-
chometric properties in addition to unidimensionality
and freedom from DIF. Reproducibility (test-retest relia-
bility) was generally good ranging from 0.78 in the Neth-
erlands to 0.86 in the US. Only 22 Dutch parents
Table 3: CIAD solutions for Europe and the US
Item Europe US
Item deleted Item split by country Link item Item deleted
Other children won't play with him.
He can't join in activities with other children.
He sleeps badly most nights.
He whinges all the time.
He is very moody.
He often gets angry with me.
He cannot be comforted.
Other children don't like holding his hand.
He is often irritable.
He misses out on a lot of childhood activities.
He is very demanding.
He is often restless.
9
9 9
9 9
9 9
9
9
9
9 9
9 9
9
9
9
Table 2: Demographic information for the trial samples and the 
validation studies
European trial US trial
N 208 243
German (%) 87 (41.8)
French (%) 52 (25.0)
Dutch (%) 48 (23.1)
English (%) 21 (10.1)
American (%) 243 (100)
Male (%) 53.4 51.9
Mean (SD) age – years 4.7 (2.5) 4.0 (1.8)Health and Quality of Life Outcomes 2007, 5:45 http://www.hqlo.com/content/5/1/45
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completed questionnaires on both occasions, increasing
the uncertainty of this finding. Internal consistency was
adequate on both occasions in all countries, with alpha
coefficients ranging from 0.72 to 0.85. Scores on the CIAD
correlated between 0.38 and 0.65 with those on the Psy-
chological General Well-Being Index, indicating that the
scales, while related, measure different constructs. Finally,
scores on the measures were related, as expected, to per-
ceived severity of disease (assessed by a single global item
of current disease severity), whether or not a flare-up was
being experienced and whether or not the face or hands
were affected in all countries except Germany. The sample
in Germany was less severe than that in the other coun-
tries and this lack of variability in scores may account for
the failure to obtain statistically significant differences.
Overall it can be concluded that the different language
versions of the CIAD are valid and reliable, despite the rel-
atively low number of items included in the scale.
Application of the CIAD in the clinical trials
Demographic information for the ITT datasets in the
European and US studies are shown in Table 2. T-tests of
age and Chi2  tests of gender conducted at baseline
revealed no significant difference by treatment group in
either study. Similarly, no difference in country by treat-
ment group was found in the European study.
CIAD scores in European and US trials are shown in Table
4. Change in scores for the Elidel and placebo groups are
illustrated in Figures 1 (Europe) and 2 (US). These show
that the improvement in CIAD scores for the Elidel group
are more marked than those in the placebo group in both
trials. The outcome statistics (Table 5) indicate that these
differences were only statistically significant for the Euro-
pean trial.
The standard deviations of baseline CIAD scores were rel-
atively high indicating that the impact of AD on children
Table 4: Descriptive scores for the CIAD
Baseline Time 2 Time 3 Time 4
European trial
Total sample N 208 208 208 208
mean 32.3 24.6 22.3 22.5
SD 23.7 25.0 23.7 24.0
Elidel N 140 140 140 140
mean 32.3 23.0 20.0 20.6
SD 23.4 25.0 23.4 24.0
Conventional N 68 68 68 68
Therapy mean 32.3 28.0 27.1 26.5
SD 24.9 24.7 23.9 23.7
US trial
Total sample N 243 243 243
mean 23.9 19.9 19.1
SD 23.6 22.5 22.2
Elidel N 159 159 159
mean 24.4 19.6 18.1
SD 23.2 22.0 21.1
Vehicle N 84 84 84
mean 22.9 20.5 20.8
SD 24.5 23.7 24.0
Table 5: Outcome Statistics for CIAD
F value Df P Mean change
Elidel Placebo
European study
Time 1-Time 2 3.38 1, 205 0.055 -9.3 -4.3
Time 1-Time 3 7.20 1, 205 0.008 -12.3 -5.2
Time 1-Time 4 4.53 1, 205 0.035 -11.7 -5.8
US studies
Time 1-Time 2 0.88 1, 240 0.348 -4.9 -2.4
Time 1-Time 3 2.43 1, 240 0.120 -6.3 -2.1Health and Quality of Life Outcomes 2007, 5:45 http://www.hqlo.com/content/5/1/45
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varies considerably. Furthermore, there was a relatively
high drop out rate in the studies (62.2% in the European
trial and 40.2% in the US trial). Both factors are likely to
have reduced the ability of the CIAD to show differences
between treatment arms and suggest the need for larger
sample sizes in order to demonstrate the benefits of treat-
ment.
Discussion
The present study has succeeded in identifying a valid
instrument for assessing the impact of AD on children
(the CIAD). In order to analyze the clinical trial data in
terms of the impact of the treatment on the affected chil-
dren it was necessary to ensure both that the items fit the
measurement model and that there was no DIF associated
with cultural differences between countries in the Euro-
pean trial.
Even with careful adaptation of measures major problems
can occur where issues are valued differently in different
countries. Assuming that all items in a scale fit the meas-
urement model in a particular country no problem would
arise until there was a need to combine data from different
countries. Such amalgamation of data could lead to treat-
ment differences being masked by DIF. As clinical trials
are now frequently multinational, DIF is a major concern
that needs to be addressed when interpreting patient-
reported outcomes.
Three of the 12 draft CIAD items misfit in Europe and five
in the US and these items were excluded from the respec-
tive trial analyses. The European CIAD comprised 9 items
(3 unique to Europe) while the US measure consisted of 7
items (1 unique to the US) with 6 items being common to
both versions. However, three items that misfit in the US
were employed in the analysis of the European trial,
where they were found to fit. It is not clear why items mis-
fitted in specific countries. However, it is possible that cer-
tain translations were not sufficiently precise or that issues
were not perceived as problems in some countries. Such
issues would be expected to arise when adapting any out-
come measure for use in a new language and/or culture.
For the analysis of the European study a novel approach
was adopted in which items shown to be valued differ-
ently in different countries were treated as individual
items. This method of controlling for DIF allowed data
from the different countries to be combined in a valid
manner. Thus, while all scores were derived from a valid
PRO scale, the analyses were based on different item sets
in each country. Such an approach relies on the ability to
calibrate items from different countries onto the same
underlying metric scale, given that some items are com-
mon and can provide a linkage across countries. This pro-
vides a possible means of overcoming DIF associated with
cultural differences in QoL assessment which cannot be
avoided where a fixed set of items is employed. Previous
instrument development programmes have dealt with
such culture-related DIF by rejecting all items exhibiting
this problem (see for example, Doward et al, 2003).
Allowing items to have different values in each culture
means that items considered highly relevant by respond-
ents could be kept in the scales, even where they scale dif-
ferently in each country – thereby maintaining the face
validity of the final scale.
A weakness of the CIAD is its limited number of items. It
would be possible to increase the responsiveness of the
CIAD by generating additional items and ensuring that
the scale excludes misfitting items and others that exhibit
DIF across countries. However, such a process is relatively
time consuming and expensive.
CIAD change scores in European trial Figure 1
CIAD change scores in European trial.
CIAD change scores in US trial Figure 2
CIAD change scores in US trial.Health and Quality of Life Outcomes 2007, 5:45 http://www.hqlo.com/content/5/1/45
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The CIAD has been shown (like the PIQoL-AD) to fit the
Rasch model, providing a metric transformation of ordi-
nal data, and with the absence of significant patterns in
the residuals, a unidimensional scale. Use of the two
measures in clinical studies would allow the assessment of
the impact of AD on both the child and his or her parent,
providing a powerful test of the effectiveness of interven-
tions.
Abbreviations
AD – Atopic dermatitis; CIAD – The Childhood Impact of
Atopic Dermatitis; PCA – Principle Components Analysis;
PIQoL-AD; The Parents' Index of Quality of Life – Atopic
Dermatitis; QoL – quality of Life; PRO – Patient Reported
Outcome.
Competing interests
Three of the authors are employed by Galen Research, an
independent research company that has received sponsor-
ship by Novartis pharmaceuticals.
Authors' contributions
SM: Designed the study, conducted interviews and drafted
the manuscript.
LD: Designed the study and conducted interviews and
qualitative analysis.
DM: Undertook analyses and prepare the manuscript.
AT: Undertook analysis and reporting.
GL: Undertook analyses and reporting.
JG: Helped design the study and prepare the manuscript.
All authors read and approved the final manuscript.
References
1. Papadopoulos L, Bor R, eds: Psychological Approaches to Dermatology
Leicester: BPS Books; 1999. 
2. Pauli-Pott U, Darui A, Beckmann D: Infants with atopic dermati-
tis: maternal hopelessness, child-rearing attitudes and per-
ceived infant temperament.  Psychother Psychosom 1999,
68:39-45.
3. Finlay AY: Quality of life impairment in atopic dermatitis and
psoriasis.  Clinical and Experimental Perspectives inSandimmum Therapy
1992, 2:10-11.
4. Daud LR, Garralda ME, David TJ: Psychosocial adjustment in pre-
school children with atopic eczema.  Arch Dis Child 1993,
69:670-676.
5. Elliot BE, Luker K: The experiences of mothers caring for a
child with severe atopic eczema.  J Clin Nurs 1997, 6:241-247.
6. Finlay AY: Skin disease disability: measuring its magnitude.
Keio J Med 1998, 47:131-134.
7. McKenna SP, Whalley D, Dewar AL, Erdman RA, Kohlmann T, Niero
M, Baro E, McKenna SP, Whalley D, Dewar AL, Erdman RA, Kohl-
mann T, Niero M, Baro E, Cook SA, Crickx B, Frech F, van Assche D:
International development of the Parents' ndex of Quality of
Life in Atopic Dermatitis (PIQoL-AD).  Qual Life Res 2005,
14(1):231-41.
8. Whalley D, Huels J, McKenna SP, van Assche D: The benefit of
Pimecrolimus (Elidel ®, SDZ ASM 981) on the quality of life
of parents in the treatment of paediatric atopic dermatitis.
Pediatrics 2002, 110:1133-6.
9. Doward LC, McKenna SP, Kohlmann T, Niero M, Patrick D, Spencer
B, Thorsen H: The international development of the
RGHQoL: A quality of life measure for recurrent genital her-
pes.  Quality of Life Research 1998, 7:143-153.
10. Rasch G: Probabilistic models for some intelligence and attainment tests
Chicago: University of Chicago Press; 1960.  (Reprinted 1980)
11. Smith RM: Fit analysis in latent trait measurement models.
Journal of Applied Measurement 2000, 1(2):199-218.
12. Van Alphen A, Halfens R, Hasman A, Imbos T: Likert or Rasch?
Nothing is more applicable than a good theory.  Journal of
Advanced Nursing 1994, 20:196-201.
13. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay
LJ, McKenna SP, Tennant A, van der Heijde D, Chamberlain MA: The
Development of the ASQoL: A quality of life instrument spe-
cific to Ankylosing Spondylitis.  Ann Rheum Dis 2003, 62:20-26.
14. Helliwell PS, Marzo-Ortega H, Tennant A: Comparison of a dis-
ease specific and a generic instrument for measuring health-
related quality of life in ankylosing spondylitis.  Arthritis Rheum
2002, 46:3098.
15. Gilworth G, Chamberlain MA, Harvey A, Woodhouse A, Smith J,
Smyth MG, Tennant A: Development of a work instability scale
for rheumatoid arthritis.  Arthritis Rheum 49(3):349-54. 2003 Jun
15
16. Kucukdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A: Issues
in cross-cultural validity: example from the adaptation, reli-
ability, and validity testing of a Turkish version of the Stan-
ford Health Assessment Questionnaire.  Arthritis Rheum
51(1):14-9. 2004 Feb 15
17. McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ:
Development of the PsAQoL: a quality of life instrument
specific to psoriatic arthritis.  Ann Rheum Dis 2004, 63(2):162-9.
18. Whalley D, McKenna SP, Dewar AL, Erdman RA, Kohlmann T, Niero
M, Cook SA, Crickx B, Herdman MJ, Frech F, Van Assche D: A new
instrument for assessing quality of life in atopic dermatitis:
international development of the Quality of Life Index for
Atopic Dermatitis (QoLIAD).  Br J Dermatol 2004,
150(2):274-83.
19. Tennant A, McKenna SP, Hagell P: Application of Rasch analysis
in the development and application of quality of life instru-
ments.  Value Health :S22-S26. 2004 Sep-Oct;7
20. McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Grif-
fiths CE, Van Assche D: Development of the PSORIQoL, a pso-
riasis-specific measure of quality of life designed for use in
clinical practice and trials.  Br J Dermatol 2003, 149(2):323-31.
21. Banerji M, Smith RM, Dedrick RF: Dimensionality of an early
childhood scale using Rasch analysis and confirmatory factor
analysis.  Journal Outcome of Measurement 1997, 1(1):56-85.
22. Angoff WH: Perspectives on Differential Item Functioning
Methodology.  In Differential Item Functioning Edited by: Holland PW,
Wainer H. Hillsdale, New Jersey: Lawrence Erlbaum; 1993. 
23. Hair JF, Anderson RE: Multivariate data analysis with readings Upper
Saddle River, N.J.: Prentice Hall; 1998. 
24. Bland JM, Altman DG: Multiple significance tests: The Bonfer-
roni method.  BMJ 1995, 310:170.
25. Andrich D, Lyne A, Sheridon B, Luo G: RUMM 2010 Perth: RUMM
Laboratory; 2000. 
26. Weiner EA, Stewart BJ: Assessing Individuals Boston, Little Brown;
1984. 
27. Streiner D, Norman G: Health Measurement Scales Oxford: Oxford
University Press; 1995. 